Migard (Frovatriptan)

Frovatriptan, the active ingredient in Migard, is a Triptan presented as a 2.5 mg tablet for oral use. It is classified as an antimigraine agent (ATC code N02CC04) and is indicated for the acute treatment of migraine attacks, including migraine with aura, in adult patients.

GNH USA supplies Migard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements across EU and global markets.

Frovatriptan acts on the migraine pathway as a selective 5‑HT1B/1D receptor agonist.

- Acute migraine attack: provides rapid relief of headache and associated symptoms. - Migraine with aura: reduces headache severity when aura precedes the attack. - Menstrual migraine (short‑term prevention): may be used to lessen migraine frequency around menstruation.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: transient light‑headedness. - Fatigue: feeling of tiredness or weakness. - Dry mouth: reduced salivation. - Somnolence: mild sleepiness. - Chest discomfort: mild pressure or tightness.

Serious or Rare Side Effects: - Coronary vasospasm: severe chest pain requiring medical attention. - Myocardial infarction: heart attack symptoms. - Serotonin syndrome: agitation, hyperthermia, tremor. - Severe hypertension: sudden high blood pressure. - Allergic reactions: rash, swelling, anaphylaxis. - Cardiac arrhythmias: irregular heart rhythm.

Before using Migard, consider the following precautions: - Cardiovascular disease: avoid if you have coronary artery disease, angina, or uncontrolled hypertension. - History of stroke or TIA: contraindicated in patients with prior cerebrovascular events. - Concomitant triptans or ergotamines: do not combine with other migraine-specific agents. - Pregnancy Category C: discuss risks with a healthcare professional before use. - Hepatic impairment: use with caution; dose adjustment may be required. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Frovatriptan may interact with several medicines.

Major Interactions (Avoid): - MAO inhibitors: increase risk of serotonin syndrome. - SSRIs/SNRIs: combined use can precipitate serotonin toxicity. - Other triptans or ergot alkaloids: additive vasoconstrictive effects. - Strong CYP3A4 inhibitors: may raise frovatriptan plasma levels.

Moderate Interactions (Monitor Closely): - NSAIDs: concurrent use may raise risk of gastrointestinal bleeding. - Antihypertensives: may reduce blood‑pressure‑lowering efficacy. - Oral contraceptives: may influence migraine frequency; monitor symptom changes.